Wockhardt Recalls Famotidine Tablets Due to Complaint Investigation Failures
Wockhardt USA LLC is recalling 1,002 drums of Famotidine Tablets, USP, 10 mg because the firm did not adequately investigate customer complaints.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically indicates a temporary or medically reversible adverse health consequence. The specific issue is a documentation and process failure (failure to investigate complaints) rather than a direct contamination or defect causing immediate harm, fitting the 'Moderate' criteria for minor labeling or process errors without reported injury.
Plain-English summary
Wockhardt USA LLC is voluntarily recalling 1,002 drums of Famotidine Tablets, USP, 10 mg, packaged in 50,000-count drums for repacking only. The product is Over the Counter and was distributed nationwide in the United States, including Puerto Rico.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the firm did not adequately investigate customer complaints. The affected lots include LM10826, LM10999, LM11016, LM11032, LM11038, LM11087, LM11149, LM11156, LM11615, LN10195, LN10323, LN10500, LN10507, LN10514, LN10555, LN10556, LN10565, LN10784, LN10788, LN10831, LN10839, LN10846, LN10856, LN10884, LN10916, LN10931, LN10934, LN11067, and LN11072.
Consumers should check their inventory for these specific lot numbers and expiration dates. If the product is found, it should be returned to the distributor or disposed of according to local regulations. No specific health risks or illnesses have been reported in the source text.
The recalled product
- Product
- Famotodine Tablets, USP, 10 mg Tablets, For Repacking Only, Packaged in 50,000 Count Drums, Over the Counter. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA. NDC: 64679-0972-00.
- Manufacturer
- Wockhardt Usa Inc.
- Category
- Drug — Tablets
- Affected units
- 1,002
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: LM10826
- Expiry: 5/31/2015
- Lot #: LM10999
- Lot #: LM11016
- Expiry: 6/30/2015
- Lot #: LM11032
- Lot #: LM11038
- Lot #: LM11087
- Lot #: LM11149
- Expiry: 4/30/2015
- Lot #: LM11156
- Lot #: LM11615
- Expiry: 8/31/2015
- Lot #: LN10195
- Expiry: 12/31/2015
- Lot #: LN10323
- Lot #: LN10500
- Expiry: 1/31/2016
- Lot #: LN10507
- Lot #: LN10514
Distribution
Part of a larger recall action
This product is one of 35 recalled by Wockhardt Usa Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 35 products in this recall →Related recalls
Same manufacturer · Wockhardt Usa Inc.
See all →- LowWockhardt Recalls Enalapril Maleate Tablets Due to Impurity Failures
FDA (Drugs) · 2017-11-01
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Azithromycin Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
- ModerateWockhardt Recalls Zolpidem Tartrate Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19